Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Income from Non-Controlling Interests (2018 - 2025)

PAVmed has reported Income from Non-Controlling Interests over the past 5 years, most recently at -$1.5 million for Q4 2025.

  • For Q4 2025, Income from Non-Controlling Interests fell 416.96% year-over-year to -$1.5 million; the TTM value through Dec 2025 reached -$2.9 million, up 74.02%, while the annual FY2025 figure was -$2.9 million, 74.74% up from the prior year.
  • Income from Non-Controlling Interests for Q4 2025 was -$1.5 million at PAVmed, down from -$628000.0 in the prior quarter.
  • Over five years, Income from Non-Controlling Interests peaked at -$289000.0 in Q4 2024 and troughed at -$4.3 million in Q1 2023.
  • A 5-year average of -$2.4 million and a median of -$2.8 million in 2022 define the central range for Income from Non-Controlling Interests.
  • Biggest five-year swings in Income from Non-Controlling Interests: skyrocketed 91.43% in 2024 and later crashed 416.96% in 2025.
  • Year by year, Income from Non-Controlling Interests stood at -$2.5 million in 2021, then crashed by 67.09% to -$4.1 million in 2022, then increased by 18.0% to -$3.4 million in 2023, then skyrocketed by 91.43% to -$289000.0 in 2024, then crashed by 416.96% to -$1.5 million in 2025.
  • Business Quant data shows Income from Non-Controlling Interests for PAVM at -$1.5 million in Q4 2025, -$628000.0 in Q3 2025, and -$403000.0 in Q2 2025.